Skip to content Skip to footer
Subscribe Now
Labcorp & OPKO Health
NEWS

Labcorp to Acquire Select Assets of OPKO Health’s BioReference Health for $722M

Shots: Labcorp has entered into an agreement with OPKO Health to acquire select assets of OPKO’s wholly owned subsidiary BioReference Health, incl. its laboratory testing businesses focused on clinical & women’s health testing services, urology, corrections and certain operational assets, incl. >80 additional patient service centers As per the deal, Labcorp will pay $722M in…
20 hours ago

Read more

NEWS

Galderma to Acquire ZO Skin Health for $1.5B

Shots: Galderma signed an agreement to acquire 100% of ZO Skin Health for an enterprise value of $1.5B in an all-cash transaction, expanding its dermatological skincare portfolio alongside Cetaphil and Alastin ZO Skin Health offers more than 40 skincare products and serves over 16,500 physician, medical spa, and online accounts across more than 40 countries.…
3 days ago

Read more

NEWS

Viatris to Acquire Pacira Biosciences for $1.65B

Shots: Viatris has entered into a definitive agreement to acquire Pacira BioSciences, advancing its innovative medicines strategy and becoming a leader in non-opioid pain therapies As per the deal, Viatris will acquire Pacira for $36.5/share in cash, representing an aggregate equity value of $1.65B, with remaining shares acquired later via a second-step merger; closing is…
October 9, 2026

Read more

NEWS

Shionogi to Acquire IntraBio for $2B to Expand Rare Disease Portfolio

Shots: Shionogi announced a planned acquisition of IntraBio for $2.0B, adding AQNEURSA (levacetylleucine) and IntraBio’s rare disease capabilities to its portfolio; the transaction is expected to close between November and December 2026, subject to customary conditions and regulatory approvals AQNEURSA is approved in the US and EU for neurological manifestations of Niemann-Pick disease Type C…
October 6, 2026

Read more

NEWS

GE HealthCare to Acquire SOFIE Biosciences for $945M to Expand US PET Radiopharmaceutical Supply

Shots: GE HealthCare entered into a definitive agreement to acquire SOFIE Biosciences from Trilantic North America for $945M in cash, with the transaction expected to close in 1H’27, subject to regulatory approvals and other closing conditions. If completed, SOFIE will become part of GE HealthCare’s PDx segment The acquisition will establish GE HealthCare’s footprint in the…
October 6, 2026

Read more

NEWS

BioMarin to Acquire Alesta Therapeutics for ~$490M

Shots: BioMarin has entered into a definitive agreement to acquire Alesta Therapeutics, incl. its P-I/II asset ALE1, an oral small molecule for the treatment of hypophosphatasia As per the deal, BioMarin will acquire Alesta, with Alesta shareholders receiving $275M upfront & ~$215M in development & regulatory milestone payments Before closing, Alesta will spin out all non-ALE1…
August 19, 2026

Read more

NEWS

Alfasigma to Acquire Nordic Pharma, Expanding Rheumatology and Global Reach

Shots: Alfasigma has entered into an agreement with SEVER Life Sciences to acquire 100% of Nordic Pharma & its subsidiaries, adding the Nordimet methotrexate franchise to Alfasigma’s rheumatology portfolio alongside Jyseleca Deal will expand Alfasigma’s commercial footprint through Nordic Pharma’s direct operations across 18 EU countries, while adding platforms in Canada & Japan. The portfolio…
August 11, 2026

Read more

NEWS

Teledyne to Acquire Varex Imaging for $1.1B

Shots: Teledyne Technologies agreed to acquire Varex Imaging for $18.90 per share in cash, valuing the transaction at approximately $1.1B, incl. Varex’s equity awards & net debt Varex develops X-ray tubes, flat-panel & photon-counting detectors, high-voltage interconnects & imaging software used across medical imaging, oncology, industrial inspection, security & vehicle inspection The acquisition is expected…
August 11, 2026

Read more

NEWS

Tarsus Pharmaceuticals to Acquire Alkeus Pharmaceuticals for ~$800M

Shots: Tarsus Pharmaceuticals has entered into a definitive agreement to acquire Alkeus Pharmaceuticals, incl. its lead asset gildeuretinol (ALK-001), expanding Tarsus’ presence in retina care As per the deal, Alkeus will receive ~$450M upfront ($270M cash + $180M in Tarsus stock priced at $61.38/share), plus ~$350M in regulatory & commercial milestones, & low single-digit tiered descending…
August 6, 2026

Read more

Load more